Show simple item record

dc.creatorJuanbeltz Zurbano, Reginaes_ES
dc.creatorMartínez Baz, Ivánes_ES
dc.creatorSan Miguel Elcano, Ramónes_ES
dc.creatorGoñi Esarte, Silviaes_ES
dc.creatorCabasés Hita, Juan Manueles_ES
dc.creatorCastilla Catalán, Jesúses_ES
dc.date.accessioned2019-02-27T13:17:50Z
dc.date.available2019-02-27T13:17:50Z
dc.date.issued2018
dc.identifier.issn1932-6203 (Electronic)
dc.identifier.urihttps://hdl.handle.net/2454/32420
dc.description.abstractBackground. Direct-acting antivirals (DAA) have demonstrated high efficacy to achieve sustained virological response (SVR) in chronic hepatitis C patients. We aim to assess the change in healthrelated quality of life (HRQoL) among patients successfully treated, and to identify predictors of this variation. Methods. In a prospective observational study, patients with chronic hepatitis C who started DAA therapy between May 2016 and April 2017 completed the EQ-5D-5L questionnaire at baseline and 12 weeks after the end of therapy before knowing the virological result. Analysis included all patients with SVR. Results. Median baseline EQ-5D-5L scores of the 206 enrolled patients were 0.857 utility and 70.0 visual analogue scale (VAS). Following SVR, a reduction occurred in the proportion of patients with mobility problems (35% vs 24%, p = 0.012), pain/discomfort (60% vs 42%, p<0.001) and anxiety/depression (57% vs 44%, p = 0.012), with an increase in utility (+0.053, p<0.001) and VAS (+10, p<0.001). Score improvements were also observed in cirrhotic (+0.048 utility, p = 0.027; +15 VAS, p<0.001) and HIV co-infected patients (+0.039 utility, p = 0.036; +5 VAS, p = 0.002). In multivariate analyses, middle age (45±64 years) and baseline anxiety/depression were associated to greater improvement in utility after SVR, and moderate-advanced liver fibrosis and cirrhosis to greater increase in VAS score. Low baseline values were associated to greater improvements in utility value and VAS score. Conclusions The cure of chronic hepatitis C infection with DAA has a short term positive impact on HRQoL with improvement in mobility, pain/discomfort, anxiety/depression, utility value and VAS score. Patients with poor baseline HRQoL were the most beneficed.en
dc.format.extent15 p.
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.publisherPublic Library of Scienceen
dc.relation.ispartofPLoS ONE 13(10): e0205277en
dc.rights© 2018 Juanbeltz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectChronic hepatitis C patientsen
dc.subjectDirect-acting antiviral agentsen
dc.titleImpact of successful treatment with directacting antiviral agents on health-related quality of life in chronic hepatitis C patientsen
dc.typeinfo:eu-repo/semantics/articleen
dc.typeArtículo / Artikuluaes
dc.contributor.departmentUniversidad Pública de Navarra. Departamento de Estadística, Informática y Matemáticases_ES
dc.contributor.departmentNafarroako Unibertsitate Publikoa. Estatistika, Informatika eta Matematika Sailaeu
dc.contributor.departmentUniversidad Pública de Navarra. Departamento de Economíaes_ES
dc.contributor.departmentNafarroako Unibertsitate Publikoa. Ekonomia Sailaeu
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessen
dc.rights.accessRightsAcceso abierto / Sarbide irekiaes
dc.identifier.doi10.1371/journal.pone.0205277
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pone.0205277
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.type.versionVersión publicada / Argitaratu den bertsioaes


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2018 Juanbeltz et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Except where otherwise noted, this item's license is described as © 2018 Juanbeltz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.